Clinical Trial Detail

NCT ID NCT03319628
Title First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mersana Therapeutics
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneal carcinoma

thyroid gland papillary carcinoma

papillary renal cell carcinoma

salivary gland cancer

lung non-small cell carcinoma

endometrial carcinoma

Therapies

XMT-1536

Age Groups: adult senior

No variant requirements are available.